Compare OVV & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVV | JAZZ |
|---|---|---|
| Founded | 2020 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 16.1B |
| IPO Year | 2019 | 2007 |
| Metric | OVV | JAZZ |
|---|---|---|
| Price | $59.86 | $256.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 14 |
| Target Price | $58.35 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 3.3M | 697.4K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | ★ 13.54 | N/A |
| EPS | N/A | ★ 7.17 |
| Revenue | ★ $8,908,000,000.00 | $1,618,693,000.00 |
| Revenue This Year | $5.45 | $6.22 |
| Revenue Next Year | N/A | $7.68 |
| P/E Ratio | ★ N/A | $36.48 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.47 | $109.87 |
| 52 Week High | $64.61 | $265.05 |
| Indicator | OVV | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 65.75 |
| Support Level | $55.68 | $222.49 |
| Resistance Level | $59.91 | N/A |
| Average True Range (ATR) | 1.89 | 7.12 |
| MACD | -0.22 | 0.46 |
| Stochastic Oscillator | 24.54 | 90.54 |
Ovintiv Inc is a North American oil and natural gas exploration and production company focused on developing its multi-basin portfolio of high-quality assets located in the United States and Canada. Its operations also include the marketing of oil, NGLs, and natural gas. The company has two operating segments: USA Operations and Canadian Operations. USA Operations include the exploration, development, production, and marketing of oil, NGLs, natural gas, and other related activities within the United States. Canadian Operations include the exploration, development, production, and marketing of oil, NGLs, natural gas, and other related activities within Canada. The company generates the majority of its revenue from USA Operations.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.